Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

NCT06402201 is registered in ClinicalTrials.gov with CDR-Life AG as lead sponsor.

NCT NCT06402201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06402201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
Lead sponsor
CDR-Life AG
Phase
Phase 1
Overall status
Recruiting
Start date
May 24, 2024
Completion date
December 31, 2027
Enrollment
42 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

select advanced solid tumors